Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (November 2022)
21 slides from Infusystems's investor presentation, Nov 8, 2022
Slide 1: Investor Presentation
Investor Presentation NOVEMBER 8, 2022 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home
Slide 2: Forward-Looking Statements / Non-GAAP Measures
Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
Slide 3: Investment Highlights
Investment Highlights Enterprise Value* $210M Market Cap* $175M Shares Out 20.7M 2021 Revenue $102.4M, Up 5% y/y 2022 Revenue Guidance $113M–$116M Providing best-in-class durable medical equipment and patient services facilitating clinic-to-home care $10B U.S. and Canada Home DME market; growth driv
Slide 4: Focus, Scale and Experience
*Source: U.S. News & World Report, Best Hospitals, July 2021 Focus, Scale and Experience 4 A leading provider of equipment and services with a 100K+ device fleet in the U.S. and Canada 36-year history, perfected model in Oncology and now expanding into multiple therapies Seven major service areas in
Slide 5: Two Proven Business Platforms
Two Proven Business Platforms Growth Driven by Market Share Gains and New Therapy Opportunities DME $36.8M (36%) SALES BY SEGMENT Total 2021 Revenue: $102.4 million ITS $65.6M (64%) INTEGRATED THERAPY SERVICES (ITS) Facilitate outpatient care for patients requiring therapy utilizing durable medical
Slide 6: DME Platform
Medical Device Sale/Lease to Hospitals & Clinics Source Devices Supply Consumables to Hospitals & Clinics Device Repair & Maintenance DME Platform Traditional Medical Distribution, Lower-Margin, High-Turn Model • Pump rentals and VAR sales (new devices) Broker/trader sales (used devices) • Biomedica
Slide 7: ITS Platform
Clinical Support/Case Management Device Logistics Medical Device Revenue Cycle Management Device Repair & Maintenance ITS Platform Unique and Scalable, High-Margin, High-Service Model Supply medical equipment and proprietary consumables for outpatient care Hospital, clinician and patient customer se
Slide 8: Competitive Advantages
Competitive Advantages Significant Barriers to Entry Based on Unique Focus, National Scale and Established Payer Network Patient Wellness Patient Safety InfuSystem Online Resource is the only patient resource facilitating two-way patient and clinical team communication to maintain peace of mind. Sca
Slide 9: Growth Strategy
Growth Strategy Adding New High-Margin Therapy Segments & Biomedical Services Oncology Evaluation Go-to-Market Strategy Launch Growth/Traction Established Highly scalable infrastructure Currently evaluating multiple therapies through partnership and acquisition with multibillion-dollar TAM Leverage
Slide 10: Highly Scalable Existing Infrastructure
Highly Scalable Existing Infrastructure Offices and Logistics • Full Coverage of the U.S. and Canada (MI, KS, CA, MA, TX, Ontario) Sales and Marketing • Territories with overlapping coverage and incentive for new therapies • Staffing efficiencies to service multiple therapies Revenue Cycle Team/ Cas
Slide 11: Opportunity: Oncology Home Treatment
Opportunity: Oncology Home Treatment • Large capital expense for clinics in addition to maintenance and nightly triage • Reduced staff available to help patients with infusion pump questions and billing Solution: Outpatient Treatment • Infusion devices fleet, inventoried and ready for distribution •
Slide 12: Third Quarter Financial Results
Third Quarter Financial Results Net Revenue Net Income (Loss) AEBITDA Op Cash Flow 2022 2021 2022 2021 2022 2021 2022 2021 $27.3M $26.6M $5.6M $5.5M $3.5M $5.8M (1) See Appendix A. $0.4M $(0.4)M 12 (1)
Slide 13: Nine Months Ended Financial Results
Nine Months Ended Financial Results Net Revenue Net (Loss) Income AEBITDA Op Cash Flow 2022 2021 2022 2021 2022 2021 2022 2021 $81.1M $75.9M $15.3M $17.5M $13.0M $14.6M (1) See Appendix A. $(0.1)M $1.0M 13 (1)
Slide 14: Full Year Financial Results
Full Year Financial Results Net Revenue Net Income AEBITDA Op Cash Flow 2021 2020 2021 2020 2021 2020 2021 2020 $102.4M $97.4M $1.4M $17.3M $24.0M $26.4M $18.3M $20.3M (1) See Appendix A. 14 (1)
Slide 15: Financial Trend & Current 2022 Guidance
2018A 2019A 2020A 2021A 2022E $0 $20 $40 $60 $80 $100 $120 $140 $ $5 $10 $15 $20 $25 $30 $35 Notes: 1. See Appendix A. Revenue ($ M illions) Financial Trend & Current 2022 Guidance Annual Net Revenue Annual AEBITDA Q3 YTD Net Revenue Q3 YTD AEBITDA A EBITD A ($ M illions) 15 Net Revenues & AEBITDA(1
Slide 16: Financial Trends
Financial Trends Annual Cash Flows From Operations Annual % of Pro Forma Net Revenue Q3 YTD Cash Flows From Operations 16 2018A 2019A 2020A 2021A 2022A $0.0 $1.5 $3.0 $4.5 $6.0 $7.5 $9.0 $10.5 $12.0 $13.5 $15.0 $16.5 $18.0 $19.5 $21.0 $22.5 $24.0 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 18.0% 20.0% 22.0% 2
Slide 17: Executive Team
Executive Team Seasoned Industry Experience, Including: Pharmaceutical, Health Care, Life Sciences, Medical Device, Automotive OEM, Public Accounting, Military, Retail, Consumer Brands, Digital Advertising, Consulting, Information Technology & High-Tech Jeannine Lombardi Sheehan – Executive Vice Pre
Slide 18: Summary
Summary Two proven platforms that enable the delivery of patient care from the clinic into the home, driving double-digit revenue, cash flow growth and accelerating profit Market opportunities driven by rising health care costs, an aging population, medical innovation, patient satisfaction and other
Slide 19: Questions & Answers
(InfuSystem SAFE. SMART. TRUSTED: Questions & Answers
Slide 20: Appendix A GAAP to Non-GAAP Reconciliation
Appendix A GAAP to NON-GAAP Reconciliation (1) Amounts represent a non-cash expense recorded as a reserve for missing medical equipment and is being added back due to its similarity to depreciation. Amounts for the prior period, which were not previously included in the calculation of adjusted EBITD
Slide 21: Appendix B Select Balance Sheet Data
(1) Calculated as the cash plus borrowing availability under revolving bank loans. Appendix B Select Balance Sheet Data (In Thousands) December 31, 2020 December 31, 2021 September 30, 2022 Cash and Cash Equivalents $ 9,648 $ 186 $ 363 Available Liquidity (1) $ 20,436 $ 41,612 $ 40,057 Working Capit
InfuSystem Holdings — Investor Presentation (November 2022) on 6ix